000			04832nam a22006617a 4500
008			190314s20192019 xxu||||| |||| 00| 0 eng d
022			_a1526-6028
024			_a10.1177/1526602818806653 [doi]
040			_aOvid MEDLINE(R)
099			_a30681021
245			_aStent Placement Across the Renal Vein Inflow in Patients Undergoing Venous Reconstruction Preserves Renal Function and Renal Vein Patency: Experience in 93 Patients.
251			_aJournal of Endovascular Therapy. 26(2):258-264, 2019 04.
252			_aJ Endovasc Ther. 26(2):258-264, 2019 04.
252			_zJ Endovasc Ther. :1526602818806653, 2019 Jan 25
253			_aJournal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
260			_c2019
260			_fFY2019
265			_saheadofprint
265			_sppublish
266			_d2019-03-14
268			_aJournal of Endovascular Therapy. :1526602818806653, 2019 Jan 25
520			_aCONCLUSION: Stent placement across the renal vein inflow did not compromise renal function. A very small risk of renal vein thrombosis was seen.
520			_aMETHODS: Between June 2008 and September 2016, 93 patients (mean age 39 years, range 15-70; 54 women) with iliocaval occlusion underwent venous stent placement and were retrospectively reviewed. For this analysis, the patients were separated into treatment and control groups: 51 (55%) patients had suprarenal and infrarenal iliocaval venous disease requiring inferior vena cava stent reconstruction across the renal vein inflow (treatment group) and 42 (45%) patients had iliac vein stenting sparing the renal veins (control group). Treatment group patients received Wallstents (n=15), Gianturco Z-stents (n=24), or suprarenal and infrarenal Wallstents such that the renal veins were bracketed with a "renal gap" (n=12). Stenting technical success, stent type, glomerular filtration rate (GFR), and creatinine before and after stent placement were recorded, along with renal vein patency and complications.
520			_aPURPOSE: To determine if stent placement across the renal vein inflow affects kidney function and renal vein patency.
520			_aRESULTS: All procedures were technically successful. In the 51-patient treatment group, 15 (29%) patients received Wallstents and 24 (47%) received Gianturco Z-stents across the renal veins, while 12 (24%) were given a "renal gap" with no stent placement directly across the renal vein inflow. In the control group, 42 patients received iliac vein Wallstents only. Mean prestent GFR was 59+/-1.8 mL/min/1.73 m<sup>2</sup> and mean prestent creatinine was 0.8+/-0.2 mg/dL for the entire cohort. Mean prestent GFR and creatinine values in the Wallstent, Gianturco Z-stent, and "renal gap" subgroups did not differ from the iliac vein stent group. Mean poststent GFR and creatinine values were 59+/-3.3 mL/min/1.73 m<sup>2</sup> and 0.8+/-0.3 mg/dL, respectively. There were no differences between mean pre- and poststent GFR (p=0.32) or creatinine (p=0.41) values when considering all patients or when comparing the treatment subgroups and the control group. There were no differences in the poststent mean GFR or creatinine values between the Wallstent (p=0.21 and p=0.34, respectively) and Gianturco Z-stent (p=0.43 and p=0.41, respectively) groups and the "renal gap" group. One (1%) patient with a Wallstent across the renal veins developed right renal vein thrombosis 7 days after the procedure.
546			_aEnglish
650			_a*Angioplasty, Balloon/is [Instrumentation]
650			_a*Renal Veins/pp [Physiopathology]
650			_a*Stents
650			_a*Vascular Diseases/th [Therapy]
650			_a*Vascular Patency
650			_aAdolescent
650			_aAdult
650			_aAged
650			_aAngioplasty, Balloon/ae [Adverse Effects]
650			_aBiomarkers/bl [Blood]
650			_aCreatinine/bl [Blood]
650			_aFemale
650			_aGlomerular Filtration Rate
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aRenal Veins/dg [Diagnostic Imaging]
650			_aRetrospective Studies
650			_aRisk Factors
650			_aTreatment Outcome
650			_aVascular Diseases/dg [Diagnostic Imaging]
650			_aVascular Diseases/pp [Physiopathology]
650			_aVenous Thrombosis/et [Etiology]
650			_aYoung Adult
651			_aMedStar Washington Hospital Center
656			_aSurgery/Vascular Surgery
657			_aJournal Article
700			_aAbramowitz, Steven D
790			_aAbramowitz SD, Brewerton C, Bundy JJ, Chick JFB, Coleman DM, Fenlon JB, Gemmete JJ, Hage AN, Srinivasa RN, Williams DM
856			_uhttps://dx.doi.org/10.1177/1526602818806653 _zhttps://dx.doi.org/10.1177/1526602818806653
942			_cART _dArticle
999			_c4111 _d4111